Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.
about
Mechanism of action of lenalidomide in hematological malignanciesThalidomide analogues as anticancer drugsImmunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacyAn international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsLenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanomaThe emerging role of lenalidomide in the management of lymphoid malignanciesThe evolving role of lenalidomide in the treatment of hematologic malignancies.Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.Treatment of plasma cell dyscrasias with lenalidomide.Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.Mechanism of action of immunomodulatory agents in multiple myeloma.Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.Lenalidomide in solid tumors.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.Emerging drugs for diffuse large B-cell lymphoma.A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaEvaluation of US 2016/0115161 A1: isoindoline compounds and methods of their use.The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.Gab adapter proteins as therapeutic targets for hematologic disease.Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletionExtranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.
P2860
Q21198872-5F27EB22-3BBE-437E-AEE8-49DE679D709DQ24670383-155EC4D1-57E2-4DB0-983F-B66A3783186EQ30659342-AB2034C3-599A-4D75-9BF2-72A0FA3FF6DCQ33393623-DB903ED2-6E9F-4E56-96A0-DAB36C03FB3CQ34220013-FE430B24-9A50-4FEC-B5E9-266E1B246509Q34719436-0EF3AD4E-38E1-4BA2-B083-70CC5014815FQ35171777-A4313F25-A687-48FB-AFB1-53D09A0FBE3DQ35828711-A061094B-ACAF-4403-849B-E51D254E0916Q35844148-6F009903-FCC6-4D23-81E4-6F418ACC64A5Q35928569-43173685-2D4F-4D72-B64D-E26F045B462FQ36612543-EE8CDE4B-CEEB-40CF-9C42-10398946C18BQ36739807-8825AD2F-F417-4B26-B42E-94103CECC025Q36936541-56725137-6B22-4EAD-AC06-2F30253F0620Q37176044-83652A48-C2C9-4E08-AF81-CE4ADDE508A5Q37280938-1392270F-2564-4E0B-B948-9F35A7B21473Q37293324-9B39D7C2-6CE2-45B8-893E-4EE43645A72EQ37734280-59A30BDD-3246-45F4-B9B7-009A8CCDE589Q37799831-0EC3E5E5-53A7-48D2-91EE-9C5F5AEF3835Q37864686-9144314B-D21A-45DE-9399-DB683D82CFD4Q38010055-5B51AE23-FCDC-42F4-A7B7-751F55E7C949Q38074017-B6AFFFE0-ECBA-4D93-A2E7-C0A08C7F3EEEQ38130301-CACB91D3-D61B-4CC9-9454-3BBE7B4D6424Q38344404-BD2B143D-B521-4ED9-89C2-374D96203BB0Q38364912-E441A9A8-FA29-484F-B154-2AECE6237763Q38551337-73348E21-7CDA-4A66-A2ED-E7F192AD1F0FQ38689884-C68DADCC-8F43-4FEC-8B93-7D63BA0E7B18Q38940707-3819B5B5-3087-4F9E-8C69-CD2861DADA7FQ39343246-CF57C031-4303-4F4F-8AC9-DF9B264915C5Q39463711-FFB66EB9-56D6-485F-8716-676E997979D7Q39627268-AB5C255E-2EEF-4F98-B094-34C76B36782FQ39744017-47DCC2BD-E0B5-4AE1-8AF5-2F706ABE4056Q39998279-4066DEC9-7C49-4E7A-B9EA-2EB802BC4FD7Q42253318-878F9915-136C-4816-86C4-1AB9B1B7D7AAQ43104067-C5E814AB-3988-4547-A26B-45A4DB55C91F
P2860
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Lenalidomide inhibits prolifer ...... ptor protein complex assembly.
@en
type
label
Lenalidomide inhibits prolifer ...... ptor protein complex assembly.
@en
prefLabel
Lenalidomide inhibits prolifer ...... ptor protein complex assembly.
@en
P2093
P1433
P1476
Lenalidomide inhibits prolifer ...... ptor protein complex assembly.
@en
P2093
Anastasia Parton
Anita K Gandhi
David I Stirling
Peter H Schafer
Syedah Naziruddin
P304
P356
10.1016/J.LEUKRES.2006.01.010
P577
2006-02-21T00:00:00Z